21 October 2021>: Articles
Treatment of Severe Immune Thrombocytopenic Purpura Associated with COVID-19
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Educational Purpose (only if useful for a systematic review or synthesis), Rare coexistence of disease or pathology
Nayab Ahmed A* , Abdullah Asreb E , Rosemary Chofor E , Achenef Melese ADOI: 10.12659/AJCR.932557
Am J Case Rep 2021; 22:e932557
Figure 2. The figure depicts the change in the platelet count over a period of 4 weeks over which the patient continued to receive prednisone and weekly rituximab. Week 0 depicts the platelet count on the day of discharge, post first dose of rituximab. Over the course of 4 weeks, the platelet count continued to trend upward.